Health2Sync, Sanofi Partner to Digitize Insulin Management in Japan

Taiwan-based digital health startup Health2Sync and French multinational pharmaceutical firm Sanofi have signed another partnership to bring digital solutions for insulin management to Japan.

What is it about

According to a press release, the two companies will jointly develop digitized features on insulin in Japan, including attached caps and titration warnings for insulin.

Health2Sync has a mobile health app that is currently used by about 290,000 patients in Japan.

Why it matters

Recent A study by the Japan Diabetes Clinical Data Management Study Group found that the average HbA1c level increased in people living with diabetes mellitus. It further noted that Japanese patients received an average of 14.8 units of baseline insulin with 7.8% HbA1c, suggesting that the dose of basal insulin could be further optimized through appropriate procedures. However, constantly recording blood glucose levels can be difficult for diabetics who are already struggling to control their disease in an unstable environment.

Health2Sync and Sanofi claim that their digital solutions will help improve insulin management among healthcare providers and diabetics in Japan.

This latest partnership “emphasizes the company’s ambition to realize more comprehensive chronic disease management through digital solutions,” a press statement said.

Greater trend

Health2Sync and Sanofi first one in 2020 Digital health program that has provided digital solutions to more than 200 clinics and more than 10,000 insulin patients across Asia.

The companies last year They have expanded their partnership to co-develop an automated digital insulin management solution with titration algorithms, which are now being studied for their therapeutic effects.

Both companies still have plans to expand their partnerships to bring digital therapeutic solutions to patients and healthcare professionals in Japan and other markets.

Leave a Reply

Your email address will not be published.